Skip to main content
. Author manuscript; available in PMC: 2014 Apr 24.
Published in final edited form as: Brain Res. 2013 Feb 21;1507:97–104. doi: 10.1016/j.brainres.2013.02.023

Fig. 2.

Fig. 2

Effects of murine 3K3A-APC late multiple dose therapy on neuropathological outcome after permanent dMCAO. Infarct volume (A), brain swelling (edema) (B) and regression analysis of functional outcome on forelimb use asymmetry test (C) and foot-fault test (D) versus the infarct volume at day 7 after dMCAO. Vehicle or multiple dose 3K3A-APC treatment (0.8 mg/kg intraperitoneally) were administered to F2r+/+ C57Bl6 mice at 12 h, 1, 3, 5 and 7 days after onset of ischemia. Mean±SEM, n = 5 mice/group. Pearson correlation coefficient (rs) and significance are indicated in panels C–D.